12.86
price up icon10.43%   1.215
after-market アフターアワーズ: 12.70 -0.16 -1.24%
loading
前日終値:
$11.64
開ける:
$11.93
24時間の取引高:
138.05K
Relative Volume:
1.88
時価総額:
$632.97M
収益:
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-7.15%
1か月 パフォーマンス:
-20.17%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
Value
$11.76
$13.49
1週間の範囲:
Value
$10.50
$14.63
52週間の値動き範囲:
Value
$10.50
$17.45

Agomab Therapeutics Nv Adr Stock (AGMB) Company Profile

Name
名前
Agomab Therapeutics Nv Adr
Name
セクター
Healthcare (1114)
Name
電話
-
Name
住所
-
Name
職員
0
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
AGMB's Discussions on Twitter

Compare AGMB vs VRTX, REGN, ALNY, ARGX, INSM

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
AGMB icon
AGMB
Agomab Therapeutics Nv Adr
12.86 573.16M 0 0 0 0.00
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
454.97 113.96B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
749.47 78.41B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.70 40.85B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
697.05 42.05B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
148.31 29.99B 606.42M -1.28B -997.58M -6.403

Agomab Therapeutics Nv Adr Stock (AGMB) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-03 開始されました JP Morgan Overweight
2026-03-03 開始されました Leerink Partners Outperform
2026-03-03 開始されました Morgan Stanley Overweight

Agomab Therapeutics Nv Adr (AGMB) 最新ニュース

pulisher
Mar 15, 2026

Total equity of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView

Mar 15, 2026
pulisher
Mar 15, 2026

Total liabilities of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView

Mar 15, 2026
pulisher
Mar 14, 2026

Total liabilities & shareholders' equities of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView

Mar 14, 2026
pulisher
Mar 14, 2026

Total debt of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView

Mar 14, 2026
pulisher
Mar 05, 2026

AgomAb Therapeutics NV ADR Balance Sheet – DUS:M5E - TradingView

Mar 05, 2026
pulisher
Mar 04, 2026

AgomAb Therapeutics NV ADR Cash Flow – DUS:M5E - TradingView

Mar 04, 2026
pulisher
Mar 04, 2026

EBITDA per share of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView

Mar 04, 2026
pulisher
Mar 04, 2026

AgomAb Therapeutics NV ADR Income Statement – DUS:M5E - TradingView

Mar 04, 2026
pulisher
Mar 03, 2026

AgomAb Therapeutics NV ADR Earnings and Revenue – DUS:M5E - TradingView

Mar 03, 2026
pulisher
Mar 03, 2026

Basic earnings per share (basic EPS) of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView

Mar 03, 2026
pulisher
Mar 03, 2026

Free float of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView

Mar 03, 2026
pulisher
Mar 03, 2026

This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm

Mar 03, 2026
pulisher
Mar 02, 2026

Total common shares outstanding of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Tangible book value per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Debt to assets ratio of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Cash per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Net current asset value per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Enterprise value to EBITDA ratio of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

EBITDA margin % of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

AgomAb Therapeutics NV ADR Cash Flow – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

AgomAb Therapeutics NV ADR Balance Sheet – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

EBITDA of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Diluted earnings per share (diluted EPS) of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Non-operating income (total) of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

AgomAb Therapeutics NV ADR Financial Statements – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Diluted net income available to common stockholders of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

AgomAb Therapeutics NV ADR Revenue Breakdown – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

AgomAb Therapeutics NV ADR Statistics – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Gross profit of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Net income before discontinued operations of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Operating income of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Total revenue of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Non-controlling/minority interest of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

AgomAb Therapeutics NV ADR Income Statement – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

AgomAb Therapeutics NV ADR Earnings and Revenue – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

Free float of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026
pulisher
Feb 10, 2026

Agomab closes $200 million IPO on NASDAQ - Investing.com India

Feb 10, 2026
pulisher
Feb 09, 2026

Agomab closes $200 million IPO on NASDAQ By Investing.com - Investing.com Nigeria

Feb 09, 2026
pulisher
Feb 09, 2026

Agomab Announces Closing of Initial Public Offering - Benzinga

Feb 09, 2026
pulisher
Feb 08, 2026

EQT Life Sciences-Backed AgomAb Falls After $200 Million IPO - Mint

Feb 08, 2026
pulisher
Feb 06, 2026

Agomab Therapeutics opens below IPO price in Nasdaq debut By Investing.com - Investing.com Canada

Feb 06, 2026
pulisher
Feb 05, 2026

Agomab prices IPO at $16 per share, aims to raise $200 million - Investing.com Australia

Feb 05, 2026
pulisher
Feb 05, 2026

Agomab prices IPO at $16 per share, aims to raise $200 million By Investing.com - Investing.com India

Feb 05, 2026
pulisher
Jan 31, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jan 31, 2026

Agomab Therapeutics Nv Adr (AGMB) 財務データ

Agomab Therapeutics Nv Adr (AGMB) の財務データはありません。詳細については、他の銘柄を確認してください。

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$27.36
price up icon 1.82%
$47.03
price up icon 3.20%
$53.54
price up icon 4.29%
$88.77
price up icon 2.26%
ONC ONC
$283.45
price up icon 2.81%
$148.31
price up icon 6.59%
大文字化:     |  ボリューム (24 時間):